The pursuit of medical treatments for opioid use disorder and chronic pain management often brings individuals into contact with tightly controlled pharmaceutical substances. Among these, buprenorphine—particularly in extended-release subcutaneous depot formulations like Buvidal—has transformed the landscape of addiction medicine. However, because buprenorphine is a powerful partial opioid agonist, it is heavily regulated across the globe. […]